New hope for advanced cancer patients? drug ZG005 enters phase 2 trial
NCT ID NCT06927687
First seen Jan 06, 2026 · Last updated May 14, 2026 · Updated 15 times
Summary
This study tests a new drug called ZG005 in 50 adults with advanced solid tumors that did not respond to or could not tolerate standard treatments. The main goal is to see if the drug shrinks tumors and to check for side effects. Participants receive the drug and are monitored closely over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Conditions
Explore the condition pages connected to this study.